Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carb claims rulemaking

This article was originally published in The Tan Sheet

Executive Summary

A proposed rule defining carbohydrate nutrient content claims and an advanced notice of proposed rulemaking requesting public comments on data and information on "carbohydrate-related label claims and consumer understanding and behaviors related to such claims" is expected to publish "this fiscal year," according to FDA Deputy Commissioner Medical & Scientific Affairs Scott Gottlieb, MD. The upcoming publication was announced during a speech delivered at the Grocery Manufacturers of America's "Convention on the Future of Food" Nov. 30. FDA requested approval from the Office of Management & Budget to conduct a study on consumer perception of carbohydrate label claims in August (1"The Tan Sheet" Aug. 22, 2005, p. 9)...

You may also be interested in...



FDA-Proposed Study Would Measure Reaction To “Low Carb” Label Claims

FDA is seeking clearance from the Office of Management & Budget to conduct a study that would "help enhance FDA's understanding of consumer response to carbohydrate content claims on food labels.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel